Allogeneic therapies are a holy grail for cancer-focused biotech companies, promising to speed critical treatments into a broader range of health ...
News
- Adicet soars on early clinical data for cancer cell therapy - San Francisco Business Times
- Exai Bio Secures $67.5 Million Series A Financing to Advance Next-Generation, RNA ... - BioSpace
--Founder to Present Supporting Data at San Antonio Breast Cancer Conference-- ... 2021 Vilcek Prize for Creative Promise in Biomedical Sciences ...
- Data further support pembrolizumab regimen for early triple-negative breast cancer - Healio
... extended EFS for patients with early triple-negative breast cancer, according to results presented at San Antonio Breast Cancer Symposium.
- Here is why BriaCell Therapeutics Corp. (BCTX) recent weekly performance of - Invest Chronicle
... Data Poster Presented at the 2021 San Antonio Breast Cancer Symposium®. ... a clinical-stage biotechnology company specializing in targeted ...
- Context Therapeutics gains ahead of clinical data for breast cancer candidate - Seeking Alpha
... the presentations will be conducted at the 2021 San Antonio Breast ... Context Therapeutics: A New Biotech Issue With A Low Valuation And ...